so here is the List of Top Biotech companies in Germany which are sorted out based on the total revenue.
|S/N||Company Name||Total Revenue (FY)||Number of Employees|
|1||Morphosys Ag||$ 401 Million||615|
|2||Brain Biotec Na||$ 45 Million||279|
|3||Formycon Ag||$ 42 Million||131|
|4||Biofrontera Ag Na||$ 37 Million||149|
|5||Vita 34 Ag Na||$ 25 Million||116|
|6||Heidelberg Pharma Ag||$ 10 Million||84|
|7||Medigene Ag Na||$ 10 Million||121|
|8||4Sc Ag Inh.||$ 3 Million||48|
MorphoSys AG operates as a commercial-stage biopharmaceutical company. The Company focuses on discovery, development, and delivery of innovative cancer medicines. MorphoSys serves clients worldwide.
BRAIN Biotech AG
BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. It operates through the BioScience and BioIndustrial segments.
The BioScience segment works on enzymes and performance microorganisms; and collaborates with industrial partners. The BioIndustrial segment deals with the bioproduct and cosmetics businesses. The company was founded by Holger Zinke, Jüngen Eck, and Hans Günter Gassen on September 22, 1993 and is headquartered in Zwingenberg, Germany.
Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval.
With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has six biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207.
Biofrontera Ag Na
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Leverkusen-based company develops and markets innovative products for the treatment, protection and care of the skin.
Its key products include Ameluz®, a prescription drug for the treatment of non-melanoma skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the USA since May 2016. In Europe, the company also markets the Belixos® dermocosmetic series, a specialty care product for damaged skin. Biofrontera is one of a few German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard).
Vita 34 Ag Na
Founded in Leipzig in 1997 as the first private umbilical cord blood bank in Europe, Vita 34 is a full-range supplier of cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue.
Stem cells are a valuable source material for medical cell therapies. They are kept alive at temperatures of around minus 180 degrees Celsius to be able to apply them within the scope of medical treatment, when needed. More than 230.000 customers from Germany and 20 other countries already have opened stem cell deposits with Vita 34, thus providing for the health of their children.
Heidelberg Pharma Ag
Heidelberg Pharma AG is a biopharmaceutical company working in the field of oncology. The company is focused on the development of Antibody Drug Conjugates (ADCs) for the treatment of oncological diseases. Heidelberg Pharma’s so-called ATACs are ADCs based on the ATAC technology that uses Amanitin as an active ingredient. The biological mechanism of action of the Amanitin toxin represents a new therapeutic principle.
This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Further preclinical development candidates are HDP-102, a CD37 ATAC for Non-Hodgkin lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer.
The company as well as its subsidiary Heidelberg Pharma Research GmbH is based in Ladenburg near Heidelberg in Germany. It was founded in September 1997 as Wilex Biotechnology GmbH in Munich and was changed to WILEX AG in 2000. In 2011, the subsidiary Heidelberg Pharma Research GmbH was acquired and after a restructuring, the registered office of WILEX AG was moved from Munich to Ladenburg and the name of the Company was changed to Heidelberg Pharma AG.
The subsidiary Heidelberg Pharma GmbH is now named Heidelberg Pharma Research GmbH. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard.